Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for hidradenitis suppurativa mode-of-action study
NL-OMON48592Phase 2Active, not recruiting
- Sponsor
- Nederlandse Federatie van Universitair Medische Centra
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guselkumab in hidradenitis suppurativa (HS), sponsored by Nederlandse Federatie van Universitair Medische Centra. Primary endpoints: Expression levels of inflammatory cytokine protein and mRNA in HS lesional skin and Alterations in serum protein profile. Started Oct 2019; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON48592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48592.